JPMorgan Chase & Co. Has Lowered Expectations for Bath & Body Works (NYSE:BBWI) Stock Price

Bath & Body Works (NYSE:BBWI – Get Free Report) had its price target lowered by research analysts at JPMorgan Chase & Co. from $24.00 to $23.00 in a note issued to investors on Friday, Benzinga reports. The firm presently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s target price would indicate a potential upside of 23.19% from the stock’s previous close.

Other research analysts also recently issued research reports about the stock. BMO Capital Markets decreased their target price on shares of Bath & Body Works from $24.00 to $20.00 and set a “market perform” rating for the company in a research report on Friday. Jefferies Financial Group reissued a “hold” rating and set a $21.00 price target on shares of Bath & Body Works in a research report on Thursday. Bank of America cut their price target on shares of Bath & Body Works from $30.00 to $25.00 and set a “buy” rating on the stock in a research report on Friday. Morgan Stanley reduced their price objective on shares of Bath & Body Works from $22.00 to $21.00 and set an “equal weight” rating for the company in a research note on Friday. Finally, Argus restated a “hold” rating on shares of Bath & Body Works in a report on Wednesday, September 16th. Four investment analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Bath & Body Works has a consensus rating of “Hold” and a consensus price target of $22.00.

View Our Latest Report on BBWI

Bath & Body Works Stock Down 1.3%

Shares of BBWI opened at $18.67 on Friday. The stock has a market capitalization of $3.76 billion, a P/E ratio of 5.10, a P/E/G ratio of 0.93 and a beta of 1.31. Bath & Body Works has a twelve month low of $14.27 and a twelve month high of $24.94. The company has a 50 day moving average of $19.24 and a 200-day moving average of $19.75.

Bath & Body Works (NYSE:BBWI – Get Free Report) last announced its quarterly earnings data on Thursday, November 19th. The company reported $0.26 EPS for the quarter, topping analysts’ consensus estimates of $0.12 by $0.14. The business had revenue of $1.58 billion for the quarter, compared to analyst estimates of $1.55 billion. Bath & Body Works had a net margin of 10.32% and a negative return on equity of 57.47%. The firm’s revenue for the quarter was down 1.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.37 earnings per share. Bath & Body Works has set its Q4 2026 guidance at 1.410-1.610 EPS and its FY 2026 guidance at 2.600-2.800 EPS. On average, sell-side analysts anticipate that Bath & Body Works will post 2.77 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Bath & Body Works

Several hedge funds and other institutional investors have recently made changes to their positions in BBWI. Algert Global LLC raised its position in Bath & Body Works by 36.0% during the third quarter. Algert Global LLC now owns 684,287 shares of the company’s stock worth $10,894,000 after acquiring an additional 181,023 shares in the last quarter. Ancora Advisors LLC lifted its stake in Bath & Body Works by 107,891.7% in the third quarter. Ancora Advisors LLC now owns 12,959 shares of the company’s stock valued at $206,000 after acquiring an additional 12,947 shares during the last quarter. Readystate Asset Management LP lifted its stake in Bath & Body Works by 408.8% in the third quarter. Readystate Asset Management LP now owns 579,712 shares of the company’s stock valued at $9,229,000 after acquiring an additional 465,780 shares during the last quarter. Ares Systematic Credit Ltd acquired a new stake in Bath & Body Works in the third quarter valued at $442,000. Finally, Saba Capital Management L.P. grew its position in shares of Bath & Body Works by 784.2% in the 3rd quarter. Saba Capital Management L.P. now owns 84,111 shares of the company’s stock valued at $1,339,000 after acquiring an additional 74,598 shares during the period. 95.14% of the stock is owned by institutional investors.

More Bath & Body Works News

These are some of the BBWI news items that stood out recently:

  • Positive Sentiment: The company raised its full-year sales outlook and announced a new $500 million share-repurchase program. It maintained adjusted FY2026 EPS guidance of $2.60–$2.80. Bath & Body Works Q3 results and outlook
  • Negative Sentiment: Q4 EPS guidance of $1.41–$1.61 came in below the $1.72 analyst consensus, with revenue guidance also below expectations at the midpoint. Reports of softer expected holiday sales add to concerns about near-term demand. Bath & Body Works trims FY26 EPS outlook
  • Negative Sentiment: Several firms lowered their BBWI price targets after the results, including UBS ($22 to $19), BMO ($24 to $20), and JPMorgan ($24 to $23). Most maintained neutral or equivalent ratings, signaling caution despite targets generally remaining above the recent share price. UBS Group rating and price target

About Bath & Body Works

(Get Free Report)

Bath & Body Works, Inc. is a specialty retailer focused on personal care and home fragrance products. Its offerings include body lotions, soaps, fragrances, hand sanitizers, candles and other home-fragrance items, sold under the Bath & Body Works and White Barn brands. The company serves customers through its stores and e-commerce platform in the United States and Canada, as well as through international franchise, license and wholesale partners. Bath & Body Works traces its roots to a store launched in 1990.

Further Reading

Analyst Recommendations for Bath & Body Works (NYSE:BBWI)

Receive News & Ratings for Bath & Body Works Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bath & Body Works and related companies with MarketBeat.com's FREE daily email newsletter.